SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe these achievements have established a strong foundation for the next phase of our growth and represent meaningful progress toward our objective of achieving profitability in 2027.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe this momentum is only beginning to reflect the commercial potential of our expanding product portfolio.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe the continued commercial traction of Arbli(™), combined with the early-stage commercialization of REZENOPY(™), positions us well to deliver continued sequential revenue growth as both products scale.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“As revenue increases, we believe this existing infrastructure, combined with our historically high gross margins, provides an opportunity to meaningfully improve operating performance without a proportionate increase in expenses.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe these developments provide a foundation for continued market share gains as we pursue additional formulary placements, broaden physician awareness, and expand patient access.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe the combination of accelerating revenue growth, high gross margins, and an improved operating cost structure positions Scienture to make meaningful progress toward our objective of achieving profitability in 2027.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe this infrastructure will enable us to scale revenue more efficiently, improve operating leverage, and support our goal of achieving profitability in 2027.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe Scienture is well positioned to capture market share in established pharmaceutical markets through a combination of differentiated FDA-approved products, long-term intellectual property protection, and an established commercial infrastructure.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe these initiatives will help drive continued sequential sales growth while leveraging our existing commercial infrastructure.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe these opportunities can contribute significantly to improving operating performance as sales scale.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe the combination of these initiatives positions Scienture to sustain sequential revenue growth as both products continue to scale.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“Our historically high gross margins and established commercial infrastructure provide the potential for meaningful operating leverage as sales increase, supporting our objective of achieving profitability in 2027.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“We believe the next phase of our growth will be defined by our ability to translate these commercial achievements into sustained revenue growth, improving financial performance, and ultimately profitability.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“While meaningful work remains ahead, we are encouraged by the progress we have made and confident in the opportunities before us.”

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture Holdings

“Our focus remains on disciplined execution, responsible capital allocation, and building a sustainable specialty pharmaceutical company capable of delivering long-term shareholder value.”

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture Holdings

“We believe these achievements have established a strong foundation for the next phase of our growth and represent meaningful progress toward our objective of achieving profitability in 2027.”